Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL)

0398204 - ÚMG 2014 RIV SK eng J - Článek v odborném periodiku
Leahomschi, S. - Molinsky, J. - Klánová, M. - Anděra, Ladislav - Peterka, Martin - Gasova, Z. - Klener, P. - Trněný, M. - Nečas, E. - Simonova, T. - Živný, J. - Klener, P.Jr.
Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL).
Neoplasma. Roč. 60, č. 2 (2013), s. 223-231. ISSN 0028-2685. E-ISSN 1338-4317
Institucionální podpora: RVO:68378050
Klíčová slova: leukemia * drug-resistance * TRAIL * apoptosis * BCL2 family
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 1.642, rok: 2013

Disruption of apoptotic pathways belongs to commonly reported molecular mechanisms that underlie cancer drug resistance. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, Apo2L) is a cytokine of the TNF family with selective anti-tumor activity and minimal toxicity toward healthy tissues. Primary leukemia cells are, however, largely intrinsically resistant to TRAIL-induced apoptosis. In this study we analyzed molecular differences between TRAIL-resistant K562 cell line and TRAIL-sensitive K562 clones. We demonstrate that TRAIL-sensitive K562 cells differ from the TRAIL-resistant cell line by cell surface downregulation of TRAIL decoy receptor 1, upregulation of both TRAIL death receptors, enhanced assembly and improved functioning of the death-inducing signaling complex, and increased cytoplasmic protein expression of CASP8 and key proapoptotic BCL2 members BID, BIM, BAD and BAK. The molecular basis of the intrinsic leukemia cell TRAIL resistance thus appears a consequence of the multi-level disruption of the extrinsic apoptotic pathway. The results of this study also suggest that the leukemia TRAIL-resistance is functional, leaving a possibility of overcoming the resistance by preexposure of the leukemia cells to potent TRAIL sensitizers, e.g. BH3-mimetics.
Trvalý link: http://hdl.handle.net/11104/0228408